---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-275595"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2024-12-11T23:59:59+00:00"
generated_at: "2026-05-29T04:35:12.463370+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acadia sells Rare Pediatric Disease PRV for $150M, one third to partner Neuren

## Summary
- Closed sale of PRV for $150M on Dec 11, 2024, after HSR waiting period expired.
- PRV awarded March 2023 from FDA approval of DAYBUE (trofinetide) for Rett syndrome.
- One third of net proceeds payable to Neuren under July 2023 joint venture agreement.
- Material terms of PRV Transfer Agreement previously disclosed in Q3 2024 10-Q.

## SEC filing metadata
- accession: 0001193125-24-275595
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2024-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312524275595/0001193125-24-275595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312524275595/d841090d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-275595
- JSON: https://secwatch.observer/filing/0001193125-24-275595.json
- Plain text: https://secwatch.observer/filing/0001193125-24-275595.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.